EP0237073A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
IL-1alpha derivatives and drugs
Assignee: Otsuka Pharmaceutical Co Ltd
•
Filing: 1987-03-12
•
Granted: —
•
Expires: 2007-03-12
Abstract
Abstract An interleukin-1 (IL-1α) derivative having a modified amino acid sequence of IL-1α, a gene coding for said derivative, medicinal composition comprising said derivative as a pharmaceutically effective component and a medicinal use of homogeneous IL-1α.
Inventors
- 👤 Satoru 67-4 Aza-Minamikawamuko Nakai
- 👤 Mayumi 1-81 Higashinakasu Kaneta
- 👤 Yoshikazu Haitsu-Datemusume B-302 Kikumoto
- 👤 Yeong-Man Sanraunjihausu 105 Hong
- 👤 Kazuyoshi Haitsu Soreiyu 503 Kawai
- 👤 Setsuko 1090-18 Kagasuno Takegata
- 👤 Kiyoshi 39-46 Aza-Sakafuji Ishii
- 👤 Yasuo Yanagihara
- 👤 Yoshikatsu 5-49 Aza-Ekogawa Hirai
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 16:45
CPC Classifications
C; C12; C12N; C12N15/00; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/54; C07K14/545; A; A61; A61P; A61P29/00; A61P35/00; A61P37/00; A61P37/02; A61P37/04; A61P43/00; C12N1/00; F; F16; F16L; F16L5/00; F16L5/02; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/82
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
44 words
A polypeptide having an amino acid sequence of IL-1α represented by the formula (A) which is modified in that at least one of Asn at the 36 position and Cys at the 141 position is deficient or replaced by another amino acid: formula (A)
Claim 2
Dependent Claim
44 words
A polypeptide having an amino acid sequence of IL-1α represented by the formula (A) which is modified in that at least one of Asn at the 36 position and Cys at the 141 position is deficient or replaced by another amino acid: formula (A)
Claim 3
Dependent Claim
32 words
A polypeptide as defined in claim 1 having the amino acid sequence of the formula (A) wherein at least Asn at the 36 position is deficient or replaced by another amino acid.
Claim 4
Dependent Claim
26 words
A polypeptide as defined in claim 1 having the amino acid sequence of the formula (A) wherein Asn at the 36 position is replaced by Asp.
Claim 5
Dependent Claim
35 words
A polypeptide as defined in claim 1 having the amino acid sequence of the formula (A) wherein Asn at the 36 position and Cys at the 141 position are respectively replaced by Asp and Ser.
Claim 6
Dependent Claim
11 words
A gene coding for the polypeptide as defined in claim 1.
Claim 7
Dependent Claim
10 words
A vector containing the gene as defined in claim 5.
Claim 8
Dependent Claim
10 words
A microorganism containing the vector as defined in claim 6.
Claim 9
Dependent Claim
21 words
A medicinal composition comprising a pharmacologically effective amount of the polypeptide as defined in claim 1 and a medicinal auxiliary agent.
Claim 10
Dependent Claim
15 words
A medicinal composition as defined in claim 8 which is a composition for stimulating immunity.
Claim 11
Dependent Claim
17 words
A medicinal composition as defined in claim 8 which is a composition for curing a malignant tumor.
Claim 12
Dependent Claim
18 words
A medicinal composition as defined in claim 8 which is a composition for promoting production of a cytokine.
Claim 13
Dependent Claim
15 words
A medicinal composition as defined in claim 8 which is a composition for curing inflammation.
Claim 14
Dependent Claim
18 words
A medicinal composition as defined in claim 8 which is a composition for preventing or curing radiation injury.
Claim 15
Dependent Claim
21 words
A medicinal composition for promoting production of CSF comprising a pharmacologically effective amount of human IL-1α and a medicinal auxiliary agent.
Claim 16
Dependent Claim
21 words
A medicinal composition for promoting production of CSF comprising a pharmacologically effective amount of human IL-1α and a medicinal auxiliary agent.
Claim 17
Dependent Claim
21 words
A medicinal composition for curing a malignant tumor comprising a pharmacologically effective amount of human IL-1α and a medicinal auxiliary agent.
Claim 18
Dependent Claim
21 words
A medicinal composition for curing a malignant tumor comprising a pharmacologically effective amount of human IL-1α and a medicinal auxiliary agent.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.